Anaphylaxis Treatment Made Easier With New, Enhanced Twinject De

Dual-dose device provides back-up medication for severe allergic reactions

Verus Pharmaceuticals, Inc. today announced the availability of its enhanced Twinject epinephrine auto-injector for anaphylaxis. Twinject is the only auto-injector with two doses of epinephrine in a single, compact device.

"Verus is committed to providing innovative solutions for anaphylaxis patients and their caregivers," said Robert W. Keith, President and Chief Operating Officer of Verus. "The enhanced Twinject is one of several line extensions and next generation products we have in our current anaphylaxis pipeline and we are pleased to bring this easier to train and simpler to use product to market in the U.S."

Anaphylaxis is a severe, life-threatening allergic reaction triggered by exposure to one or more various antigens, including foods, insect stings, drugs, and latex products. Up to 43 million people in the U.S. alone are at risk for anaphylactic episodes, and underlying incidence rates are expected to continue increasing in future years. Up to eight percent of children have food allergies, and sensitivities to peanuts and tree nuts among children have doubled in the past five years.